{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:59:26Z","timestamp":1791665966346,"version":"4.3.4"},"reference-count":23,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,6,18]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is no effective systemic therapy for metastatic adrenal cortical carcinoma (ACC) after failure of platinum-based chemotherapy. The efficacies of single-agent oral multikinase inhibitors (MKIs) or salvage immune checkpoint inhibitors (CPIs) have been very limited. It is unknown whether combining CPIs, such as pembrolizumab (PEM), with other therapies, such as MKIs, could yield higher response rates in ACC, yet this combination has shown promise in other cancers. Herein, we describe the first case series using PEM in combination with the MKI lenvatinib (LEN) in patients with progressive, metastatic ACC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective case series describing the use of LEN\/PEM as salvage therapy in patients with progressive\/metastatic ACC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eight patients were treated with the LEN\/PEM combination therapy. Half were female, and the median age at time of diagnosis was 38 years (range 21\u201349). Three (37.5%) patients had hormonally active ACC. The median number of prior lines of systemic therapy was 4 (range 2\u20139). Six (75%) patients had had disease progression on prior CPIs and five (62.5%) patients had progressed on prior MKI therapy. The median progression-free survival was 5.5 months (95%\u2009CI 1.8\u2013not reached) and median duration of therapy was 8.5 months (range 2\u201322). Two (25%) patients had a partial response, one (12.5%) patient had stable disease, and five (62.5%) patients had progressive disease. None of the eight patients stopped therapy because of adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In our small cohort of heavily pretreated patients with ACC, the combination of LEN\/PEM was associated with objective responses in a subset of patients without significant toxicity. This combination should be formally investigated in phase II clinical trial with robust correlative studies to identify predictors for response.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-001009","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T03:28:14Z","timestamp":1596166094000},"page":"e001009","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":55,"title":["Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03370718","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03612232","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1396-6384","authenticated-orcid":false,"given":"Sara","family":"Bedrose","sequence":"first","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Section of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Charles","family":"Miller","sequence":"additional","affiliation":[{"name":"School of Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Altameemi","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S","family":"Ali","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Diabetes and Metabolism, University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Nassar","sequence":"additional","affiliation":[{"name":"Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyne","family":"Daher","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D","family":"Eaton","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Thomas","family":"Yorio","sequence":"additional","affiliation":[{"name":"Texas Oncology Austin Central, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davey B","family":"Daniel","sequence":"additional","affiliation":[{"name":"Tennessee Oncology, Chattanooga, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith C","family":"Bible","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Ryder","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish V","family":"Chintakuntlawar","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-9637","authenticated-orcid":false,"given":"Mouhammed Amir","family":"Habra","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"2025100309575770000_8.2.e001009.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200966"},{"key":"2025100309575770000_8.2.e001009.2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3"},{"key":"2025100309575770000_8.2.e001009.3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0918"},{"key":"2025100309575770000_8.2.e001009.4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2298"},{"key":"2025100309575770000_8.2.e001009.5","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0722-x"},{"key":"2025100309575770000_8.2.e001009.6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0424-9"},{"key":"2025100309575770000_8.2.e001009.7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"Pd-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100309575770000_8.2.e001009.8","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase Ib\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100309575770000_8.2.e001009.9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025100309575770000_8.2.e001009.10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0378-y"},{"key":"2025100309575770000_8.2.e001009.11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2217\/fon-2018-0745","article-title":"Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale","volume":"15","author":"Gr\u00fcnwald","year":"2019","journal-title":"Future Oncol"},{"key":"2025100309575770000_8.2.e001009.12","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S188316"},{"key":"2025100309575770000_8.2.e001009.13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24030"},{"key":"2025100309575770000_8.2.e001009.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100309575770000_8.2.e001009.15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1419"},{"key":"2025100309575770000_8.2.e001009.16","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2011.00027","article-title":"Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells","volume":"2","author":"Kroiss","year":"2011","journal-title":"Front Endocrinol"},{"key":"2025100309575770000_8.2.e001009.17","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0231"},{"key":"2025100309575770000_8.2.e001009.18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3707"},{"key":"2025100309575770000_8.2.e001009.19","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100309575770000_8.2.e001009.20","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1210\/js.2019-00305","article-title":"Response to immunotherapy in combination with mitotane in patients with metastatic adrenocortical cancer","volume":"3","author":"Head","year":"2019","journal-title":"J Endocr Soc"},{"key":"2025100309575770000_8.2.e001009.21","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci"},{"key":"2025100309575770000_8.2.e001009.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"2025100309575770000_8.2.e001009.23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2018.07.016","article-title":"The ambitious role of anti angiogenesis molecules: turning a cold tumor into a hot one","volume":"70","author":"Nuti","year":"2018","journal-title":"Cancer Treat Rev"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:58:07Z","timestamp":1759510687000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,30]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/jitc-2020-001009"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001009","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}